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INTRODUCTION
Metabolites of drugs can possess in vivo pharmacologic, toxicologic or enzyme inhibitory activity and contribute to the clinical effects of the drug (Ho et al., 2003; Riss et al., 2008) . For example, the secondary metabolite of clopidogrel, R-130964, is the primary active species that is responsible for the anti-coagulant effect in vivo, and decreasing its abundance in vivo leads to decreased pharmacological effect (Angiolillo et al., 2010) . The role of metabolites in drug toxicity is illustrated by the removal of fenfluramine from the US market due to its association with valvular heart disease. This cardiovascular toxicity was proposed to be 5-HT 2B receptormediated and norfenfluramine, the N-deethylated metabolite of fenfluramine, was demonstrated to be a significantly more potent agonist of human 5-HT 2B receptors than fenfluramine (Fitzgerald et al., 2000) . The inhibition of cytochrome P450 (CYP) 2D6 following bupropion administration appears to be mainly due to the primary metabolites of bupropion rather than bupropion itself, demonstrating the potential role of metabolites in inhibitory drug-drug interactions (Reese et al., 2008; Yeung et al., 2010) . Due to the concern of exposures to metabolites in humans that are not covered by preclinical safety testing, the US Food and Drug for early identification of metabolites and prediction of metabolite exposures (Anderson et al., 2009; Leclercq et al., 2009) .
Metabolic ratios such as the metabolite/parent area under the plasma concentration versus time curve ratio (AUC m /AUC p ), plasma concentration of the metabolite/parent (C m /C p ) or urinary concentration ratios are commonly used in drug-drug interaction and pharmacogenetic studies as in vivo activity measures of the CYP mediating the formation of the metabolite. Use of metabolite formation or a metabolic ratio instead of an area under the plasma concentration versus time curve (AUC) of the parent drug is necessary when the parent drug is only partially cleared by the CYP isoform of interest. Commonly used metabolic ratios include the hydroxybupropion/bupropion ratio for CYP2B6, the paraxanthine/caffeine ratio for CYP1A2, the dextrorphan/dextromethorphan ratio for CYP2D6 and the 5-hydroxyomeprazole/omeprazole ratio for CYP2C19 (Jones et al., 1996; Streetman et al., 2000; Yu and Haining, 2001; Abduljalil et al., 2010) . The 3-methoxymorphinan/dextromethorphan and omeprazole sulfone/omeprazole ratios have also been proposed as CYP3A4 probes (Jones et al., 1996; Bertilsson et al., 1997; Böttiger et al., 1997; Tu et al., 2010) . In general, a decrease in the metabolic ratio is interpreted as inhibition of the P450 forming the metabolite or a poor metabolizer phenotype, whereas an increase suggests induction of the specific metabolic pathway. All metabolite/parent ratios are dependent on the formation and elimination clearances of the metabolite and their interpretation relies on the assumption that the clearance of the metabolite is not affected by the treatment or the genotype studied (Levy et al., 1983) . However, the elimination pathways and relative contribution of specific enzymes for the clearance of the metabolite may be inadequately characterized, and the effect of interacting drug on the probe metabolite clearance is rarely DMD #42200
Page 7 determined. Hence, the interpretation of the metabolic ratio may be confounded by changes in metabolite clearance.
A method for predicting the in vivo metabolite/parent AUC m /AUC p using clearance scaling from in vitro metabolite formation and elimination data was proposed and tested using literature data for 6 metabolite/parent pairs (Lutz et al., 2010) . The proposed method could be useful for a priori prediction of the relative metabolite exposure in vivo before clinical testing, or for identification of important secondary metabolism of metabolites whose AUC m /AUC p are greatly over-predicted after clinical administration. To test the method, published in vitro data for the formation of 3-hydroxymorphinan from dextrorphan ( Figure 1 ) (Kerry et al., 1994) and 5-hydroxyomeprazole sulfone from 5-hydroxyomeprazole (5OH-omeprazole) ( Figure 2 ) (Andersson et al., 1993; Andersson et al., 1994) , was used to predict in vivo AUC m /AUC p ratios for dextrorphan/dextromethorphan and 5OH-omeprazole/omeprazole. The metabolite/parent AUC ratios were over-predicted by 160-and 20-fold, for dextrorphan/dextromethorphan and for 5OH-omeprazole/omeprazole, respectively, indicating that significant uncharacterized metabolic pathways exist for dextrorphan and 5OH-omeprazole. The aim of this study was to determine whether these elimination pathways do exist, and whether the dextrorphan/dextromethorphan, 5OH-omeprazole/omeprazole and omeprazole sulfone/omeprazole in vivo AUC m /AUC p could be accurately predicted using in vitro metabolism data. Finally, the effect of altered secondary metabolism on in vivo AUC m /AUC p was tested via pharmacokinetic simulation. Liver Bank (Seattle, WA, USA). All seven donors were both phenotyped and genotyped to confirm that they were CYP2C19 and CYP2D6 extensive metabolizers as well as CYP3A5 nonexpressors to avoid potential confounding effects of CYP3A5 expression in metabolite formation and elimination. Recombinantly expressed UDP-glucuronsyltransferase (rUGT) enzymes were obtained from BD Biosciences (Sparks, MD, USA). For all pooled HLM incubations, 0.1 mg microsomal protein (mg MP)/mL was used. All CYP-mediated incubations were performed in 100 mM potassium phosphate (KPi) buffer at 37˚C, after a 10 minute pre-incubation with substrate at 37˚C to achieve binding equilibrium. The incubations were then initiated with 1 mM final concentration of NADPH cofactor. For pooled HLM and rUGT dextrorphan-O-glucuronide formation, the incubations were first pre-incubated with 50 µg/mg MP alamethicin and 5 mM saccharolactone on ice in 100 mM KPi buffer for 30 minutes to allow insertion of the alamethicin pore former into the microsomal membrane, then further pre-incubated at 37˚C for This article has not been copyedited and formatted. The final version may differ from this version. The hepatocyte incubations were analyzed utilizing an Agilent Infinity 1290 UPLC coupled to an AB Sciex API5500 Q/LIT mass spectrometer operated in positive ion electrospray mode.
The separation and detection settings for omeprazole and its metabolites were identical to those described above. The injection volume was 10 μ L.
Data analysis: All data was fit via linear or nonlinear regression numerical analysis utilizing GraphPad Prism v.5 (LaJolla, CA, USA). Unless otherwise noted, all parameter estimates are given as mean ± standard deviation. The maximum primary or secondary metabolite formation velocity (V max ) and total Michaelis-Menten affinity constant (K M ) in pooled HLMs was determined by the equation:
where v and [S] 0 are the metabolite formation velocity and initial substrate concentration, respectively. The primary or secondary metabolite total intrinsic formation clearance (Cl i,f ) was determined by the equation:
The primary metabolite total intrinsic depletion clearance (Cl i,dep ) was determined utilizing the equation:
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Prediction of AUC m /AUC p :
The in vivo AUC m /AUC p for a specific metabolite/parent pair after oral administration was predicted from in vitro data using equations 6 and 7.
Equation 6 assumes that all metabolite formed in the liver is available to the systemic circulation the metabolite, respectively and hepatic plasma flow is denoted as Q h . A value of 49.5 L/hr was used for Q h (product of the hepatic blood flow and the proportion of blood that is plasma).
To accommodate likely sequential metabolism of the metabolites within the liver before they reach systemic circulation, equation 7 was derived. For equation 7, the formation of the metabolite within the liver is considered analogous to portal vein dosing of the metabolite.
Equation 7 is obtained from equation 6 by adding an additional bioavailability term for the metabolite (F h = 1 -ER h in which ER h is the hepatic extraction ratio of the metabolite) that represents the fraction of metabolite formed in the liver that is not sequentially metabolized prior to reaching the systemic circulation (Pang and Gillette, 1979) . Incorporation of this metabolite bioavailability term yields equation 7:
For predictions, all in vitro determined total Cl or Cl i values were divided by the corresponding f u,mic value to obtain the unbound clearance (Cl u or Cl i,u ) values. For all hepatocyte data, the f u,mic was assumed to equal unity, due to the use of protein-free hepatocyte maintenance media during the incubations. The accuracy of the prediction was determined by the ratio of the predicted value over the observed value, extracted from the literature for in vivo studies that determined both parent and metabolite AUC in plasma. Only in vivo studies in CYP2D6 and CYP2C19 extensive metabolizers as determined by dextromethorphan phenotype or CYP2C19 genotype were used.
Simulations of the effect of secondary metabolism on AUC m /AUC p : Using a generic scheme of one enzyme (E1) forming a single metabolite (M) from parent drug (P) and two This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS

In vitro formation and elimination of dextrorphan:
The formation kinetics of dextrorphan from dextromethorphan was determined in pooled HLMs ( Figure 3A) . Pooled HLMs were also used to characterize 3-hydroxymorphinan and dextrorphan-O-glucuronide formation from dextrorphan ( Figure 3B and 3C) . The kinetic parameters for dextrorphan, 3-hydroxymorphinan and dextrorphan-O-glucuronide formation as well as the f u,mic and plasma f u values are summarized in Table 1 (Table 1) . To identify the UGT isoforms responsible for dextrorphan glucuronidation, dextrorphan was incubated with a panel of 12 recombinant UGT isoforms ( Figure 3D ). All four UGT2B isoforms studied (2B4, 2B7, 2B15 and 2B17), but none of the eight UGT1A isoforms Table 2) . When the glucuronidation pathway of dextrorphan is accounted for, dextrorphan is predicted to be a high extraction ratio metabolite and hence it is likely that only a fraction of the formed metabolite is available to systemic circulation. Therefore equation 7 was also used for predicting the AUC m /AUC p of dextrorphan (Table 2) . Indeed, when the glucuronidation characterized in vitro in the presence of 2% BSA and the 3-hydroxymorphinan formation were included, a predicted AUC m /AUC p of 1.3 was obtained resulting in an approximately 2-fold over-prediction.
In vitro formation and elimination kinetics of 5OH-omeprazole and omeprazole sulfone:
The total intrinsic formation (Cl i,f ) and elimination (Cl i,dep ) clearances for 5OH-omeprazole and This article has not been copyedited and formatted. The final version may differ from this version. omeprazole sulfone were determined in pooled HLMs and in cryopreserved plated human hepatocytes. Since comprehensive characterization of the secondary metabolites of omeprazole sulfone and 5OH-omeprazole is not available, the depletion clearances of these metabolites were measured instead of specific secondary metabolite formation clearance. The K M and V max for the formation of 5OH-omeprazole and omeprazole sulfone from omeprazole, as well as the depletion of these two metabolites in HLMs, is shown in Figure 4 . The kinetic parameters for 5OH-omeprazole and omeprazole sulfone formation and depletion in HLMs and human hepatocytes are summarized in Table 3 . In pooled HLMs, the unbound formation and depletion clearances for omeprazole sulfone were 7.7 µL/min/mg MP and 35 µL/min/mg MP, respectively, demonstrating that the clearance of omeprazole sulfone is 5 times faster than its formation.
Similarly, in human hepatocytes ( Figure 5 ) the elimination clearance of omeprazole sulfone (Cl i,dep = 48 ± 6 µL/hr/10 6 cells) was approximately 13 times faster than the formation of omeprazole sulfone (Cl i,f = 3.6 ± 0.5 µL/hr/10 6 cells).
The unbound formation clearance for 5OH-omeprazole in HLMs was 8.2 µL/min/mg MP but no depletion of 5OH-omeprazole was observed in pooled HLMs (Figure 4 ) and the percent remaining of 5OH-omeprazole at 30 and 60 minutes when incubated with and without NADPH was similar. Since the in vitro-to-in vivo predictions of 5OH-omeprazole exposure suggested that 5OH-omeprazole is metabolically cleared, but no depletion of 5OH-omeprazole could be observed in pooled HLMs, the depletion of 5OH-omeprazole was studied in cultured human hepatocytes ( Figure 5 ). Unlike in HLMs, depletion of 5OH-omeprazole was detected in plated human hepatocytes. The Cl i,f for 5OH-omeprazole was 55 ± 2 µL/hr/10 6 cells and the Cl i,dep for 5OH-omeprazole was 100 ± 20 µL/hr/10 6 cells.
This article has not been copyedited and formatted. The final version may differ from this version. respectively, when the elimination of the metabolite was not entirely mediated by the same enzyme which forms the metabolite (Metabolite's f m,E1 < 1, Figure 6 ). This effect was attenuated when the metabolite was cleared partly by the same enzyme that forms it and no change in the AUC m /AUC p was observed when the metabolite was entirely eliminated by the same enzyme This article has not been copyedited and formatted. The final version may differ from this version. Although the dextrorphan/dextromethorphan AUC m /AUC p was predicted within 2.1-fold using HLM data alone, based on the predictions with 5OH-omeprazole and omeprazole sulfone, use of hepatocytes is more reliable for metabolite depletion studies than HLMs. Based on the in vitro formation clearances, glucuronidation is the major elimination pathway for dextrorphan. In this study, dextrorphan-O-glucuronide formation measured in the presence of 2% BSA was 12-fold more efficient than the formation of 3-hydroxymorphinan. The overall prediction accuracy suggests that the major elimination pathways of dextrorphan are accounted for via glucuronidation and 3-hydroxymorphinan formation. UGT2B isoforms were found to be responsible for dextrorphan glucuronidation, similar to related opioids morphine and codeine (Court et al., 2003) . Dextrorphan glucuronidation has been previously reported in vitro and in vivo (Duché et al., 1993; Takashima et al., 2005; Abduljalil et al., 2010) from hepatocytes than from HLMs, but in vivo data of clearance of omeprazole sulfone would be needed to determine this. It is noteworthy that since omeprazole sulfone is 12.7-fold more bound in plasma than omeprazole (Table 3) , the unbound AUC m /AUC p of omeprazole sulfone/omeprazole is 0.067 while the observed total AUC m /AUC p is 0.85 (Table 2) . This shows that when AUC m /AUC p ratios are used to predict the importance of metabolites in pharmacologic activity, the difference between the plasma f u for the metabolite and parent should be considered together with the AUC m /AUC p .
The AUC m /AUC p for 5OH-omeprazole/omeprazole could not be predicted from HLM data due to the lack of measurable depletion of 5OH-omeprazole. Based on the reported formation kinetics of 5-hydroxyomeprazole sulfone from 5OH-omeprazole (Andersson et al., 1994) , 0.5 % depletion is expected in HLMs (0.1 mg/mL) after a 60 min incubation. This is not sufficient to obtain depletion kinetic estimates. 5OH-omeprazole and carboxyomeprazole are the major metabolites detected in urine after omeprazole administration (Renberg et al., 1989) and sequential formation of carboxyomeprazole from omeprazole aldehyde is likely responsible for the majority of 5OH-omeprazole depletion in hepatocytes. It is likely that alcohol and aldehyde dehydrogenases (ADHs and ALDHs, respectively) form omeprazole aldehyde and carboxylic acid in human hepatocytes since the ADH isoforms that metabolize xenobiotics are localized in the cytosol and expressed in the liver (Crabb et al., 2004) . Since ADH enzymes are induced by ethanol (Kawashima et al., 1996; Crabb et al., 2004) their activity is expected to vary between individuals. This may explain the considerable variability (up to 10-fold) observed in the AUC m /AUC p of 5OH-omeprazole/omeprazole between reported in vivo studies even after controlling for CYP2C19 genotype (Tassaneeyakul et al., 2000; Shirai et al., 2001 ).
This article has not been copyedited and formatted. The final version may differ from this version. (Yang et al., 2009; Tu et al., 2010) . For the dextrorphan/dextromethorphan and 5OH-omeprazole/omeprazole ratios, it is unlikely that major changes in secondary pathways would be misinterpreted if AUC p is measured in the study. However, if the change in the metabolic ratio is weak (suggesting that no effect in the less sensitive AUC p measure would be expected) or only a single time point ratio is measured, the possibility of misinterpretation is high. The challenge of identifying the correct interpretation of AUC m /AUC p ratios is emphasized by the simulations that show that induction of metabolite clearance has an identical effect on the AUC m /AUC p as inhibition of the formation of the metabolite. In addition, the simulations show that the sensitivity of the metabolic ratio is greatly dampened if the metabolite clearance is partially mediated by the same enzyme as the formation, with no effect on the ratio if the same enzyme This article has not been copyedited and formatted. The final version may differ from this version. 
